|
liver transplantation |
71 |
|
hepatocellular carcinoma |
56 |
|
adult |
51 |
|
humans |
47 |
|
female |
38 |
|
male |
37 |
|
medical sciences |
37 |
|
middle aged |
37 |
|
hepatectomy |
33 |
|
aged |
28 |
|
recurrence |
27 |
|
surgery |
27 |
|
gastroenterology medical sciences |
26 |
|
hcc |
25 |
|
prognosis |
25 |
|
retrospective studies |
25 |
|
treatment outcome |
25 |
|
survival analysis |
24 |
|
liver cancer |
23 |
|
living donors |
23 |
|
survival |
22 |
|
graft survival |
21 |
|
hong kong - epidemiology |
21 |
|
follow-up studies |
20 |
|
adolescent |
19 |
|
cirrhosis |
19 |
|
time factors |
19 |
|
immunosuppressive agents - therapeutic use |
18 |
|
liver transplantation - methods |
18 |
|
antiviral agents - therapeutic use |
17 |
|
liver resection |
17 |
|
survival rate |
17 |
|
aged, 80 and over |
16 |
|
cadaver |
16 |
|
disease-free survival |
16 |
|
gastroenterology |
16 |
|
hepatectomy - methods |
16 |
|
hepatocellular carcinoma (hcc) |
16 |
|
immunohistochemistry |
16 |
|
liver cirrhosis |
16 |
|
liver transplantation - adverse effects |
16 |
|
transarterial chemoembolization |
16 |
|
age factors |
15 |
|
blood transfusion |
15 |
|
cell proliferation |
15 |
|
disease progression |
15 |
|
liver transplant |
15 |
|
reverse transcriptase polymerase chain reaction |
15 |
|
laparoscopic liver resection |
14 |
|
outcomes |
14 |
|
case report |
13 |
|
cohort studies |
13 |
|
enzyme-linked immunosorbent assay |
13 |
|
hepatitis b |
13 |
|
incidence |
13 |
|
infant |
13 |
|
inflammation |
13 |
|
liver function tests |
13 |
|
liver transplantation - immunology |
13 |
|
living donor liver transplant |
13 |
|
portal vein |
13 |
|
postoperative complications |
13 |
|
reoperation |
13 |
|
ablation |
12 |
|
acute hepatitis |
12 |
|
arginine methylation |
12 |
|
bronchiectasis |
12 |
|
cancer stemness |
12 |
|
carcinoma, hepatocellular - mortality - surgery |
12 |
|
chemicals and cas registry numbers |
12 |
|
child |
12 |
|
child, preschool |
12 |
|
chronic obstructive lung disease |
12 |
|
drug therapy, combination |
12 |
|
liver diseases - surgery |
12 |
|
liver neoplasms - mortality - surgery |
12 |
|
liver neoplasms - pathology - surgery |
12 |
|
living donor |
12 |
|
meld |
12 |
|
organ size |
12 |
|
pediatric liver transplantation |
12 |
|
tissue donors |
12 |
|
acute disease |
11 |
|
acute flare |
11 |
|
apoptosis |
11 |
|
body mass index |
11 |
|
cancer staging |
11 |
|
cancer survival |
11 |
|
carcinoma, hepatocellular - surgery |
11 |
|
carrier state |
11 |
|
decompensation |
11 |
|
emergencies |
11 |
|
hepatitis b infection |
11 |
|
high-intensity focused ultrasound |
11 |
|
intraoperative complications - epidemiology |
11 |
|
laparoscopy |
11 |
|
liver failure |
11 |
|
liver neoplasms - surgery |
11 |
|
liver transplantation - statistics & numerical data |
11 |
|
long-term outcome |
11 |
|
metastasis |
11 |
|
outcome |
11 |
|
prospective studies |
11 |
|
tumor recurrence |
11 |
|
allergology and immunology |
10 |
|
alpps |
10 |
|
antigens, cd - genetics - metabolism |
10 |
|
biliary anastomotic stricture |
10 |
|
bridging therapy |
10 |
|
carcinoma, hepatocellular - mortality - pathology - surgery |
10 |
|
cyclosporine - therapeutic use |
10 |
|
dna primers |
10 |
|
hepatitis b, chronic - complications |
10 |
|
hong kong |
10 |
|
hospital mortality |
10 |
|
immunosuppression |
10 |
|
lamivudine |
10 |
|
length of stay |
10 |
|
liver neoplasms - mortality - pathology - surgery |
10 |
|
liver transplantation - methods - statistics and numerical data |
10 |
|
living donors - supply and distribution |
10 |
|
morbidity |
10 |
|
new technology |
10 |
|
postoperative complications - epidemiology |
10 |
|
resection |
10 |
|
scarce deceased donors |
10 |
|
surgery medical sciences |
10 |
|
tissue donors - supply and distribution |
10 |
|
vascular surgical procedures - methods |
10 |
|
11c-acetate |
9 |
|
animals |
9 |
|
bile ducts - surgery |
9 |
|
blood loss, surgical |
9 |
|
body weight |
9 |
|
cancer invasion |
9 |
|
carcinoma |
9 |
|
carcinoma, hepatocellular - pathology - surgery |
9 |
|
chronic disease |
9 |
|
contrast ct |
9 |
|
endocrinology |
9 |
|
epigenetics |
9 |
|
gpx3 |
9 |
|
hifu |
9 |
|
hipsc-mscs |
9 |
|
hospitals, university |
9 |
|
invasion |
9 |
|
invasiveness |
9 |
|
lamivudine - therapeutic use |
9 |
|
liver circulation - physiology |
9 |
|
liver diseases - epidemiology |
9 |
|
liver failure - surgery |
9 |
|
liver transplantation - mortality |
9 |
|
living donor liver transplantation |
9 |
|
milan criteria |
9 |
|
mortality |
9 |
|
neoplasm staging |
9 |
|
non-invasive treatment |
9 |
|
palliative care |
9 |
|
pet/ct |
9 |
|
postoperative complications - classification - epidemiology |
9 |
|
rats |
9 |
|
rats, sprague-dawley |
9 |
|
reverse transcriptase inhibitors - therapeutic use |
9 |
|
right liver graft |
9 |
|
severity of illness index |
9 |
|
tumor-initiating cells |
9 |
|
acetic acid c 11 |
8 |
|
advanced cancer |
8 |
|
antiviral agents - adverse effects - therapeutic use |
8 |
|
antiviral therapy |
8 |
|
base sequence |
8 |
|
bile leak |
8 |
|
biliary atresia |
8 |
|
biliary atresia - complications - surgery |
8 |
|
biliary complications |
8 |
|
bilirubin - blood |
8 |
|
cadaver donor |
8 |
|
cancer recurrence |
8 |
|
carcinoma, hepatocellular - complications/diagnosis - surgery |
8 |
|
carcinoma, hepatocellular - genetics - metabolism |
8 |
|
carcinoma, hepatocellular - metabolism - pathology |
8 |
|
carcinoma, hepatocellular - surgery - virology |
8 |
|
cardiac function |
8 |
|
carrier proteins - metabolism |
8 |
|
cell division - physiology |
8 |
|
cell line, tumor |
8 |
|
chemokine cxcl1 - physiology |
8 |
|
cholangiocarcinoma |
8 |
|
colorectal cancer |
8 |
|
combined modality therapy |
8 |
|
complications of liver transplantation |
8 |
|
cyclin-dependent kinase inhibitor p16 - genetics - metabolism |
8 |
|
deceased donor liver transplantation |
8 |
|
disease severity |
8 |
|
dose-response relationship, drug |
8 |
|
elasticity imaging techniques - methods |
8 |
|
fluorodeoxyglucose f 18 |
8 |
|
focal adhesion kinase 2 - metabolism |
8 |
|
general surgery |
8 |
|
gist |
8 |
|
glycoproteins - deficiency - genetics - metabolism |
8 |
|
glycoproteins - genetics - metabolism |
8 |
|
guanine - adverse effects - analogs and derivatives - therapeutic use |
8 |
|
heme oxygenase-1 |
8 |
|
hepatectomy - adverse effects |
8 |
|
hepatectomy - methods - mortality |
8 |
|
hepatic encephalopathy - surgery |
8 |
|
hepatitis b antibodies |
8 |
|
hepatitis b, chronic - complications - diagnosis - drug therapy - surgery |
8 |
|
hepatitis b, chronic - pathology |
8 |
|
inhibitor of differentiation protein 1 |
8 |
|
interleukin-8 - deficiency - genetics - physiology |
8 |
|
ischemia-reperfusion injury |
8 |
|
laparoscopic resection |
8 |
|
liver |
8 |
|
liver cirrhosis - pathology - virology |
8 |
|
liver cirrhosis - surgery - virology |
8 |
|
liver disease |
8 |
|
liver diseases - etiology - surgery |
8 |
|
liver failure - etiology - surgery |
8 |
|
liver failure - pathology - virology |
8 |
|
liver graft injury |
8 |
|
liver metastasis |
8 |
|
liver neoplasms - complications/diagnosis - surgery |
8 |
|
liver neoplasms - genetics - metabolism |
8 |
|
liver neoplasms - metabolism - pathology |
8 |
|
liver transplantation - adverse effects - statistics & numerical data |
8 |
|
liver transplantation - contraindications - methods - mortality - statistics & numerical data |
8 |
|
living-donor liver transplantation |
8 |
|
living-related liver transplantation |
8 |
|
marginal graft |
8 |
|
medicine & public health |
8 |
|
microscopy, electron |
8 |
|
mitochondrion |
8 |
|
multivariate analysis |
8 |
|
neoplasm recurrence, local - surgery |
8 |
|
neoplastic cells, circulating - pathology |
8 |
|
nitric oxide synthase type ii |
8 |
|
organ size - physiology |
8 |
|
orthotopic liver transplantation |
8 |
|
patient selection |
8 |
|
pediatric liver transplant |
8 |
|
portoenterostomy, hepatic |
8 |
|
postoperative care |
8 |
|
postoperative complications - prevention & control |
8 |
|
preoperative care |
8 |
|
prevention |
8 |
|
proportional hazards models |
8 |
|
radiofrequency ablation |
8 |
|
reduced-size liver transplant |
8 |
|
reduced-size liver transplantation |
8 |
|
renal transplantation |
8 |
|
repressor proteins |
8 |
|
retinoblastoma protein - genetics - metabolism |
8 |
|
rna, messenger - genetics - metabolism |
8 |
|
salvage transplantation |
8 |
|
sensitivity and specificity |
8 |
|
seroconversion (sc) |
8 |
|
steatosis |
8 |
|
stereotactic body radiation therapy |
8 |
|
thrombosis - diagnosis - etiology - surgery |
8 |
|
tissue donors - statistics & numerical data |
8 |
|
tki |
8 |
|
transcription factors - genetics - metabolism - physiology |
8 |
|
tyrosine-kinase inhibitor |
8 |
|
unresectable |
8 |
|
waiting list |
8 |
|
wedge resection |
8 |
|
abdominal abscess |
7 |
|
abdominal bleeding |
7 |
|
abdominal surgery |
7 |
|
activities of daily living |
7 |
|
adenine - analogs & derivatives - therapeutic use |
7 |
|
adiponectin |
7 |
|
adiponectin - blood - chemistry - genetics |
7 |
|
adiponectin oligomeric form |
7 |
|
adjuvant therapy |
7 |
|
alanine transaminase - blood |
7 |
|
american society of anaesthesiologists (asa) |
7 |
|
anastomosis, roux-en-y |
7 |
|
anastomosis, surgical |
7 |
|
anastomosis, surgical - methods |
7 |
|
anti-steatosis |
7 |
|
asia |
7 |
|
bile duct diseases - etiology |
7 |
|
bile ducts - blood supply - surgery |
7 |
|
biliary obstruction |
7 |
|
bone marrow transplantation |
7 |
|
cadaveric transplantation |
7 |
|
cap |
7 |
|
carcinoma, hepatocellular - blood supply - drug therapy - pathology |
7 |
|
carcinoma, hepatocellular - diagnosis - pathology - surgery |
7 |
|
carcinoma, hepatocellular - enzymology - genetics |
7 |
|
carcinoma, hepatocellular - genetics - metabolism - pathology - virology |
7 |
|
carcinoma, hepatocellular - mortality - pathology - therapy |
7 |
|
cardiac surgery |
7 |
|
catheter ablation |
7 |
|
catheters, indwelling |
7 |
|
cell differentiation |
7 |
|
cell survival signaling |
7 |
|
chemokine cxcl10 - metabolism |
7 |
|
child-pugh a |
7 |
|
children |
7 |
|
chinese |
7 |
|
cholecystitis, acute - surgery |
7 |
|
cholecystostomy - instrumentation - methods |
7 |
|
cholestasis - etiology |
7 |
|
chronic hepatitis b |
7 |
|
combined resection |
7 |
|
complication |
7 |
|
cytology and histology |
7 |
|
de novo hbv |
7 |
|
de novo hepatocellular carcinoma |
7 |
|
deceased-donor liver transplantation |
7 |
|
dna-binding proteins - metabolism |
7 |
|
domino liver transplant |
7 |
|
down-regulation |
7 |
|
drug resistance, viral - genetics |
7 |
|
endothelin-1 - genetics |
7 |
|
entecavir |
7 |
|
experience |
7 |
|
extended criteria organ |
7 |
|
fatty liver - pathology - surgery |
7 |
|
fty720 |
7 |
|
gene expression profiling |
7 |
|
graft rejection |
7 |
|
graft rejection - blood - drug therapy - pathology |
7 |
|
graft survival - drug effects |
7 |
|
graft-to-recipient weight ratio |
7 |
|
head of pancreas |
7 |
|
hepatic artery - surgery |
7 |
|
hepatic microcirculation |
7 |
|
hepatitis - surgery |
7 |
|
hepatitis b - complications |
7 |
|
hepatitis b - drug therapy - prevention & control - surgery |
7 |
|
hepatitis b vaccination |
7 |
|
hepatitis b virus - genetics |
7 |
|
hepatitis b, chronic - complications - drug therapy - pathology |
7 |
|
hepatocellular |
7 |
|
hepatocytes - cytology |
7 |
|
high-intensity focused ultrasound ablation - methods |
7 |
|
histocompatibility |
7 |
|
icc |
7 |
|
indocyanine green clearance |
7 |
|
informed consent |
7 |
|
kidney transplantation |
7 |
|
limon |
7 |
|
liver - metabolism |
7 |
|
liver biopsy |
7 |
|
liver cirrhosis - blood - metabolism - pathology - virology |
7 |
|
liver diseases - congenital - mortality - surgery |
7 |
|
liver diseases - epidemiology - surgery |
7 |
|
liver neoplasms - complications - surgery |
7 |
|
liver neoplasms - diagnosis - pathology - surgery |
7 |
|
liver neoplasms - enzymology - genetics |
7 |
|
liver neoplasms - genetics - metabolism - pathology - virology |
7 |
|
liver neoplasms - mortality - pathology - therapy |
7 |
|
liver neoplasms, experimental - blood supply - drug therapy - pathology |
7 |
|
liver transplantation - adverse effects - methods |
7 |
|
liver transplantation - adverse effects - methods - mortality |
7 |
|
liver transplantation - adverse effects - methods - pathology - statistics & numerical data |
7 |
|
liver transplantation - methods - physiology |
7 |
|
living donors - classification |
7 |
|
logistic models |
7 |
|
long-term survival |
7 |
|
macrophage |
7 |
|
mafld |
7 |
|
malignancy |
7 |
|
matrix metalloproteinase 9 - metabolism |
7 |
|
metabolic syndrome |
7 |
|
microsurgery |
7 |
|
microvascular anastomosis |
7 |
|
model for end-stage liver disease |
7 |
|
molecular weight |
7 |
|
nafld |
7 |
|
neovascularization, pathologic - drug therapy |
7 |
|
nitric oxide synthase - metabolism |
7 |
|
olt |
7 |
|
oncology medical sciences |
7 |
|
pegylated interferon alfa-2a |
7 |
|
percutaneous transhepatic cholecystostomy (ptc) |
7 |
|
phosphonic acids |
7 |
|
portal vein resection |
7 |
|
post-transplantation lymphoproliferative disease |
7 |
|
postoperative complications - prevention & control - surgery |
7 |
|
proline-rich tyrosine kinase2 (pyk2) |
7 |
|
ptbd |
7 |
|
pulse spectrophotometry |
7 |
|
radiology and nuclear medicine pharmacy and pharmacology biology |
7 |
|
rats, inbred lew |
7 |
|
recurrent hcc |
7 |
|
registries |
7 |
|
retransplantation |
7 |
|
right-lobe |
7 |
|
rna, messenger - metabolism |
7 |
|
sepsis - prevention & control |
7 |
|
small-for-size syndrome |
7 |
|
solid organ transplantation |
7 |
|
split graft liver transplant |
7 |
|
stat5 transcription factor - biosynthesis - genetics - metabolism |
7 |
|
stents |
7 |
|
survival outcomes |
7 |
|
sustained virological response |
7 |
|
thoracic surgery |
7 |
|
thrombosis - prevention & control |
7 |
|
transcription factors - metabolism |
7 |
|
transplantation |
7 |
|
transplantation, homologous |
7 |
|
transthyretin |
7 |
|
usg-guided |
7 |
|
val30ala |
7 |
|
vascular surgery |
7 |
|
vcte |
7 |
|
whipple operation |
7 |
|
acute kidney injury - surgery |
6 |
|
acute pancreatitis |
6 |
|
adefovir |
6 |
|
adrenal cortex hormones - administration & dosage |
6 |
|
akt signaling pathway |
6 |
|
angiogenesis |
6 |
|
angiopoietin-like 4 |
6 |
|
antibodies, monoclonal - administration & dosage - therapeutic use |
6 |
|
antigens, viral - blood |
6 |
|
antineoplastic agents - adverse effects - therapeutic use |
6 |
|
antineoplastic agents, hormonal - administration & dosage |
6 |
|
azathioprine - therapeutic use |
6 |
|
biliary reconstruction |
6 |
|
biliary stricture |
6 |
|
blotting, western |
6 |
|
bowel preparation |
6 |
|
breast cancer |
6 |
|
cancer |
6 |
|
cancer metabolism |
6 |
|
carcinoma, hepatocellular - complications - surgery |
6 |
|
carcinoma, hepatocellular - diagnosis - therapy |
6 |
|
carcinoma, hepatocellular - drug therapy - mortality |
6 |
|
carcinoma, hepatocellular - drug therapy - pathology - surgery - virology |
6 |
|
carcinoma, hepatocellular - epidemiology - surgery |
6 |
|
carcinoma, hepatocellular - genetics - metabolism - pathology |
6 |
|
carcinoma, hepatocellular - genetics - mortality - pathology - surgery - therapy |
6 |
|
carcinoma, hepatocellular - genetics - prevention and control - secondary |
6 |
|
case-matched study |
6 |
|
cd133 |
6 |
|
cd274 |
6 |
|
cdna microarray |
6 |
|
cell adhesion molecules |
6 |
|
cell cycle - genetics |
6 |
|
cell cycle proteins - genetics |
6 |
|
chemokines |
6 |
|
chemoresistance |
6 |
|
cholangiograms |
6 |
|
cisplatin |
6 |
|
close resection margin |
6 |
|
colorectal liver metastasis |
6 |
|
complex liver resection |
6 |
|
controlled study |
6 |
|
cyclin-dependent kinase inhibitor p21 |
6 |
|
cytokines |
6 |
|
cytomegalovirus - immunology |
6 |
|
daptomycin |
6 |
|
decolonization |
6 |
|
desmosplastic reaction |
6 |
|
diabetes mellitus - epidemiology - prevention & control |
6 |
|
diagnostic imaging |
6 |
|
dna, viral - blood |
6 |
|
donor hepatectomy |
6 |
|
duct-to-duct anastomosis |
6 |
|
ductal anomaly |
6 |
|
elderly |
6 |
|
en-bloc resection |
6 |
|
end-stage liver disease |
6 |
|
endoscopic retrograde cholangiography |
6 |
|
endoscopic treatment |
6 |
|
endothelin-1 - genetics - metabolism |
6 |
|
endothelium, vascular - pathology |
6 |
|
epithelial-mesenchymal transition |
6 |
|
erc |
6 |
|
extracellular signal-regulated map kinases - metabolism |
6 |
|
family history |
6 |
|
focal adhesion kinase |
6 |
|
gastrin |
6 |
|
gene expression |
6 |
|
gene expression regulation |
6 |
|
gene expression regulation - physiology |
6 |
|
genes, p53 - genetics |
6 |
|
glycolysis |
6 |
|
graft |
6 |
|
graft injury |
6 |
|
graft rejection - epidemiology - prevention & control |
6 |
|
graft-weight-to-recipient-weight ratio |
6 |
|
heme oxygenase (decyclizing) - genetics |
6 |
|
hepatic veins - surgery |
6 |
|
hepaticojejunostomy |
6 |
|
hepatitis b - prevention & control - surgery |
6 |
|
hepatitis b e antigens - blood |
6 |
|
hepatitis b surface antigens - analysis |
6 |
|
hepatitis b surface antigens - analysis - blood |
6 |
|
hepatitis b, chronic - mortality - surgery |
6 |
|
hepatocellular carcinomas |
6 |
|
hepatocellullar carconoma |
6 |
|
hepatocholangiocarcinoma |
6 |
|
hfe |
6 |
|
histone modifications |
6 |
|
homeodomain proteins - antagonists and inhibitors - genetics - metabolism |
6 |
|
homeodomain proteins - genetics - metabolism |
6 |
|
homeoprotein six1 |
6 |
|
hypertension, portal - etiology - physiopathology |
6 |
|
immunoglobulins - therapeutic use |
6 |
|
immunosuppressive agents - administration & dosage - therapeutic use |
6 |
|
inflammasomes |
6 |
|
inflammatory response |
6 |
|
inflow |
6 |
|
injections, intravenous |
6 |
|
interference |
6 |
|
interferon-alpha - adverse effects - therapeutic use |
6 |
|
intragraft gene expression profiles |
6 |
|
intrahepatic cholangiocarcinoma |
6 |
|
kc |
6 |
|
keywords |
6 |
|
kidney neoplasms - genetics - prevention and control - secondary |
6 |
|
lactobacillus rhamnosus gg |
6 |
|
ldlt |
6 |
|
ligation |
6 |
|
linezolid |
6 |
|
lipocalins |
6 |
|
liver - blood supply - metabolism - pathology - surgery |
6 |
|
liver - blood supply - pathology |
6 |
|
liver - pathology |
6 |
|
liver - pathology - ultrasonography |
6 |
|
liver neoplasms - blood supply - surgery - ultrastructure |
6 |
|
liver neoplasms - diagnosis - therapy |
6 |
|
liver neoplasms - drug therapy - mortality |
6 |
|
liver neoplasms - drug therapy - pathology - surgery - virology |
6 |
|
liver neoplasms - epidemiology - surgery |
6 |
|
liver neoplasms - genetics - metabolism - pathology |
6 |
|
liver neoplasms - genetics - mortality - pathology - surgery - therapy |
6 |
|
liver neoplasms, experimental - genetics - pathology - prevention and control |
6 |
|
liver neoplasms, experimental - metabolism - pathology - surgery |
6 |
|
liver resection (lr) |
6 |
|
liver transplantation (lt) |
6 |
|
liver transplantation - adverse effects - immunology |
6 |
|
liver transplantation - adverse effects - pathology - physiology |
6 |
|
liver transplantation - pathology |
6 |
|
liver transplantation - pathology - physiology |
6 |
|
liver transplantation - physiology |
6 |
|
liver transplantation - statistics and numerical data |
6 |
|
living |
6 |
|
lung neoplasms - etiology - metabolism - secondary |
6 |
|
m2 macrophages |
6 |
|
matrix stiffness |
6 |
|
mechanoepigenetics |
6 |
|
metastases |
6 |
|
mitochondria, liver - pathology |
6 |
|
modulation |
6 |
|
mycophenolic acid - administration & dosage - analogs & derivatives |
6 |
|
neoplasm recurrence, local - etiology - metabolism - pathology |
6 |
|
neuroendocrine carcinoma |
6 |
|
neutrophil |
6 |
|
nitric oxide synthase - genetics - metabolism |
6 |
|
nitric oxide synthase type iii |
6 |
|
nomogram |
6 |
|
octreotide - administration & dosage |
6 |
|
omeprazole |
6 |
|
p21/waf1 |
6 |
|
p53 |
6 |
|
pancreatic tumor |
6 |
|
pathologic tumour-node-metastasis (ptnm) stage |
6 |
|
pediatric donor |
6 |
|
pkm2 |
6 |
|
placebos |
6 |
|
polyethylene glycol |
6 |
|
polymerase chain reaction |
6 |
|
portal pressure - physiology |
6 |
|
post-lt surveillance |
6 |
|
post-transplant recurrence |
6 |
|
postoperative period |
6 |
|
prediction |
6 |
|
predictive model |
6 |
|
predictive value of tests |
6 |
|
primary transplantation |
6 |
|
prmt6 |
6 |
|
prognostic predictor |
6 |
|
progression |
6 |
|
proliferating cell nuclear antigen |
6 |
|
proliferating cell nuclear antigen - analysis |
6 |
|
propensity score matching |
6 |
|
radiofrequency ablation (rfa) |
6 |
|
rap1 |
6 |
|
receptors, interleukin-2 - immunology |
6 |
|
recombinant fusion proteins |
6 |
|
recurrent hepatocellular carcinoma |
6 |
|
regional blood flow - physiology |
6 |
|
reperfusion injury - pathology |
6 |
|
right liver donation |
6 |
|
right-liver |
6 |
|
risk factor |
6 |
|
risk factors |
6 |
|
rna, small interfering - pharmacology |
6 |
|
short hairpin rna (shrna) |
6 |
|
simultaneous resection |
6 |
|
six1 |
6 |
|
size |
6 |
|
small-for-size fatty liver |
6 |
|
small-for-size grafts |
6 |
|
stage resection |
6 |
|
standard |
6 |
|
synchronous colorectal liver metastasis |
6 |
|
systemic therapy |
6 |
|
tacrolimus - administration & dosage |
6 |
|
tacrolimus - therapeutic use |
6 |
|
thbs2 |
6 |
|
therapeutic |
6 |
|
tissue and organ procurement - organization & administration |
6 |
|
transplantation, isogeneic |
6 |
|
tuberculosis |
6 |
|
tumor suppressor gene |
6 |
|
tumour thrombus |
6 |
|
vancomycin-resistant enterococci |
6 |
|
venous infiltration |
6 |
|
waiting lists |
6 |
|
warburg effect |
6 |
|
zollinger-ellison syndrome |
6 |
|
acute-on-chronic liver failure |
5 |
|
acute-phase reaction |
5 |
|
acute-phase reaction - metabolism - pathology |
5 |
|
adenosine - chemistry |
5 |
|
adenosinergic signaling pathway |
5 |
|
adjuvant chemotherapy |
5 |
|
adoptive transfer |
5 |
|
adrenal cortex hormones - therapeutic use |
5 |
|
akt |
5 |
|
akt survival pathway |
5 |
|
alagille syndrome |
5 |
|
albumins - genetics - metabolism |
5 |
|
aldose reductase |
5 |
|
allopurinol - chemistry |
5 |
|
alpha-fetoprotein |
5 |
|
alpha-fetoprotein (afp) |
5 |
|
amino acid substitution |
5 |
|
amyloid neuropathies, familial - surgery |
5 |
|
amyloidosis, familial - ethnology - genetics - pathology |
5 |
|
analysis of variance |
5 |
|
angioplasty - methods |
5 |
|
animal models |
5 |
|
anterior approach |
5 |
|
antibody therapy |
5 |
|
antineoplastic agents, hormonal - therapeutic use |
5 |
|
antitubercular agents - pharmacokinetics - therapeutic use |
5 |
|
anxa3 |
5 |
|
apolipoprotein c-iii |
5 |
|
apolipoproteins c - metabolism |
5 |
|
asian continental ancestry group - genetics |
5 |
|
aspartate aminotransferase |
5 |
|
aspartate aminotransferases - blood |
5 |
|
augmented reality |
5 |
|
bile duct atresia |
5 |
|
bile duct obstruction |
5 |
|
bile duct reconstruction |
5 |
|
bile leakage |
5 |
|
biopsy |
5 |
|
biopsy, needle - adverse effects - methods |
5 |
|
blood loss, surgical - prevention & control |
5 |
|
blunt trauma |
5 |
|
bone marrow transplantation - adverse effects |
5 |
|
cancer cell culture |
5 |
|
cancer stem cells |
5 |
|
carcinoma - secondary - surgery |
5 |
|
carcinoma, hepatocellular |
5 |
|
carcinoma, hepatocellular - blood - blood supply - pathology |
5 |
|
carcinoma, hepatocellular - blood - diagnosis - surgery |
5 |
|
carcinoma, hepatocellular - chemistry - drug therapy - mortality |
5 |
|
carcinoma, hepatocellular - complications - diagnosis - surgery |
5 |
|
carcinoma, hepatocellular - complications - pathology - surgery |
5 |
|
carcinoma, hepatocellular - enzymology - pathology |
5 |
|
carcinoma, hepatocellular - enzymology - pathology - ultrastructure |
5 |
|
case-control studies |
5 |
|
cause of death |
5 |
|
ccaat-enhancer-binding proteins - physiology |
5 |
|
cell fusion |
5 |
|
cell movement - physiology |
5 |
|
cell-free circulating nucleic acid |
5 |
|
chemokine cxcl2 |
5 |
|
chemokines, cxc - metabolism |
5 |
|
chemosensitization |
5 |
|
chi-square distribution |
5 |
|
cholangiocarcinoma - complications - pathology - surgery |
5 |
|
cholangiopancreatography, endoscopic retrograde - adverse effects |
5 |
|
cholangiopancreatography, endoscopic retrograde - methods |
5 |
|
cholelithiasis - complications - diagnosis - surgery |
5 |
|
cholestasis, intrahepatic - drug therapy - etiology - surgery |
5 |
|
clinical competence |
5 |
|
clonorchis sinensis |
5 |
|
colorectal neoplasms - pathology |
5 |
|
complications |
5 |
|
computer systems |
5 |
|
confidence intervals |
5 |
|
cyclin d1 |
5 |
|
cytokines - blood - genetics |
5 |
|
deceased donor |
5 |
|
deceased-donor liver re-transplantation |
5 |
|
disease transmission, infectious |
5 |
|
dna - analysis |
5 |
|
dna primers - chemistry |
5 |
|
dna probes |
5 |
|
dna, viral - metabolism |
5 |
|
dna-binding proteins - physiology |
5 |
|
donor/recipient origin |
5 |
|
double bypass |
5 |
|
down-regulation - drug effects |
5 |
|
dual portal vein |
5 |
|
early growth response protein 1 |
5 |
|
emergency medical services |
5 |
|
endosonography |
5 |
|
endothelial growth factors - blood |
5 |
|
endothelin-1 - blood - genetics |
5 |
|
endothelin-1 - metabolism |
5 |
|
energy metabolism - drug effects - physiology |
5 |
|
entpd1/cd39 |
5 |
|
enzyme activity |
5 |
|
epidermal growth factor - metabolism |
5 |
|
epithelial-mesenchymal transition - physiology |
5 |
|
et5e/cd73 |
5 |
|
evaluation studies as topic |
5 |
|
extracellular adenosine |
5 |
|
familial transthyretin amyloidosis |
5 |
|
fibrosis - drug therapy - pathology |
5 |
|
focal adhesion kinase 2 - metabolism - physiology |
5 |
|
gallstones - complications - ultrasonography |
5 |
|
glucagon - blood |
5 |
|
glutathione - chemistry |
5 |
|
glycogen synthase kinase 3 - metabolism |
5 |
|
graft failure |
5 |
|
graft rejection - drug therapy |
5 |
|
graft survival - drug effects - genetics |
5 |
|
graft survival - drug effects - immunology - physiology |
5 |
|
graft survival - physiology |
5 |
|
grp78 |
5 |
|
heme oxygenase (decyclizing) - biosynthesis |
5 |
|
hepatectomy - classification - methods |
5 |
|
hepatic artery thrombosis |
5 |
|
hepatic ischemia reperfusion injury |
5 |
|
hepatic malignancy |
5 |
|
hepatic resection |
5 |
|
hepatic senescence |
5 |
|
hepatic steatosis |
5 |
|
hepatic stellate cell (hsc) |
5 |
|
hepatic stellate cells |
5 |
|
hepatic veins - physiopathology - surgery |
5 |
|
hepatitis b - complications - drug therapy - surgery |
5 |
|
hepatitis b - complications - etiology |
5 |
|
hepatitis b antibodies - blood |
5 |
|
hepatitis b core antigens - genetics |
5 |
|
hepatitis b surface antigens - immunology |
5 |
|
hepatitis b virus |
5 |
|
hepatitis b, chronic - immunology - surgery |
5 |
|
hepatitis b, chronic - surgery |
5 |
|
hepatology |
5 |
|
hepatopancreatoduodenectomy |
5 |
|
hong kong chinese |
5 |
|
hsp70 heat-shock proteins - genetics |
5 |
|
hsp70 heat-shock proteins - metabolism |
5 |
|
hypertension - epidemiology |
5 |
|
hypertension, portal - etiology - prevention & control |
5 |
|
hypertension, portal - mortality - physiopathology - surgery |
5 |
|
hypoglycemic agents - pharmacology |
5 |
|
hypoxia |
5 |
|
iatrogenic disease |
5 |
|
immediate-early proteins |
5 |
|
immediate-early proteins - metabolism |
5 |
|
immunosuppressive agents - administration and dosage |
5 |
|
immunosuppressive agents - pharmacology |
5 |
|
in situ hybridization, fluorescence |
5 |
|
in situ nick-end labeling |
5 |
|
insulin - chemistry - pharmacology |
5 |
|
insulin receptor substrate proteins |
5 |
|
intercellular signaling peptides and proteins - metabolism |
5 |
|
interleukin-10 - biosynthesis |
5 |
|
internal medicine |
5 |
|
intracellular signaling peptides and proteins |
5 |
|
intraoperative complications |
5 |
|
ir injury |
5 |
|
kaplan-meier estimate |
5 |
|
ketone bodies - blood |
5 |
|
lamivudine - administration and dosage |
5 |
|
laparoscopic hepatectomy |
5 |
|
leukemia, myelogenous, chronic, bcr-abl positive - therapy |
5 |
|
live donor liver transplantation |
5 |
|
liver - anatomy & histology |
5 |
|
liver - anatomy & histology - drug effects - ultrastructure |
5 |
|
liver - anatomy & histology - pathology - physiopathology |
5 |
|
liver - anatomy and histology |
5 |
|
liver - drug effects - injuries - metabolism |
5 |
|
liver - metabolism - ultrastructure |
5 |
|
liver - physiology - surgery |
5 |
|
liver - radiography |
5 |
|
liver cell carcinoma |
5 |
|
liver cirrhosis - complications |
5 |
|
liver cirrhosis - complications - virology |
5 |
|
liver cirrhosis - drug therapy - etiology - surgery |
5 |
|
liver cirrhosis, experimental - surgery |
5 |
|
liver laceration |
5 |
|
liver neoplasms - blood - blood supply - pathology |
5 |
|
liver neoplasms - blood - diagnosis - surgery |
5 |
|
liver neoplasms - blood - secondary - surgery |
5 |
|
liver neoplasms - blood - surgery |
5 |
|
liver neoplasms - chemistry - drug therapy - mortality |
5 |
|
liver neoplasms - complications - diagnosis - surgery |
5 |
|
liver neoplasms - complications - pathology - surgery |
5 |
|
liver neoplasms - diagnosis - etiology - genetics - surgery |
5 |
|
liver neoplasms - enzymology - pathology |
5 |
|
liver neoplasms - enzymology - pathology - ultrastructure |
5 |
|
liver neoplasms - therapy |
5 |
|
liver remnant |
5 |
|
liver transplantation - adverse effects - mortality |
5 |
|
liver transplantation - immunology - methods - physiology |
5 |
|
liver transplantation - immunology - mortality - physiology |
5 |
|
liver transplantation - methods - mortality |
5 |
|
liver transplantation - methods - mortality - statistics & numerical data |
5 |
|
liver transplantation - methods - pathology |
5 |
|
liver transplantation - mortality - physiology - statistics & numerical data |
5 |
|
liver trauma |
5 |
|
living related donor |
5 |
|
living-donor liver re-transplantation |
5 |
|
lobectomy |
5 |
|
longitudinal studies |
5 |
|
lymphatic metastasis |
5 |
|
lymphocytes - immunology |
5 |
|
lymphokines - blood |
5 |
|
lymphoma, b-cell - etiology - genetics - pathology |
5 |
|
map kinase signaling system |
5 |
|
map kinase signaling system - drug effects - physiology |
5 |
|
mapk |
5 |
|
marrow transplantation |
5 |
|
matrix metalloproteinase-12 |
5 |
|
medical errors - adverse effects |
5 |
|
meld score biliary atresia |
5 |
|
meta-analysis |
5 |
|
metachronous primary hcc |
5 |
|
metal stent |
5 |
|
microsatellite analysis |
5 |
|
microsatellite repeats |
5 |
|
models, animal |
5 |
|
momp |
5 |
|
multidrug resistance protein 1 |
5 |
|
multiple injuries |
5 |
|
mutant |
5 |
|
mutation |
5 |
|
neoplasm invasiveness |
5 |
|
neoplasm recurrence, local - blood - diagnosis |
5 |
|
neoplasm recurrence, local - mortality |
5 |
|
neoplasm recurrence, local - mortality - pathology |
5 |
|
neoplasm seeding |
5 |
|
neoplasms, second primary - mortality - surgery |
5 |
|
neovascularization, pathologic |
5 |
|
neutrophils |
5 |
|
neutrophils migration |
5 |
|
nf-kappa b - metabolism |
5 |
|
nf-κb signaling |
5 |
|
non-operative management |
5 |
|
nuclear factor-κb |
5 |
|
nuclear family |
5 |
|
oligonucleotide array sequence analysis |
5 |
|
oncological outcomes |
5 |
|
opportunistic infections - prevention and control |
5 |
|
organ preservation |
5 |
|
organ preservation solutions - chemistry |
5 |
|
organ transplantation - adverse effects - pathology |
5 |
|
overall survival |
5 |
|
oxygenation |
5 |
|
oxylab po2 |
5 |
|
p38 mitogen-activated protein kinases - metabolism |
5 |
|
palliative care - methods |
5 |
|
pancreatic cancer |
5 |
|
pancreaticojejunostomy |
5 |
|
pancreatitis - etiology - ultrasonography |
5 |
|
pancreatitis, acute necrotizing - diagnosis - etiology - surgery |
5 |
|
pancreatoduodenectomy |
5 |
|
peld score |
5 |
|
penetrative trauma |
5 |
|
phosphoproteins - physiology |
5 |
|
plasma mrna |
5 |
|
platelet count |
5 |
|
portal vein - anatomy and histology - surgery |
5 |
|
portal vein - physiopathology - surgery |
5 |
|
portal vein reconstruction |
5 |
|
post-hepatectomy |
5 |
|
post-operative complication |
5 |
|
post-transplantation lymphoproliferative disorder |
5 |
|
postoperative complications - etiology |
5 |
|
postoperative complications - etiology - pathology |
5 |
|
prealbumin - genetics |
5 |
|
predicting scoring system |
5 |
|
prediction model |
5 |
|
preoperative care - methods |
5 |
|
probability |
5 |
|
proctology |
5 |
|
promoter regions, genetic - genetics |
5 |
|
prophylaxis |
5 |
|
propylene glycols - pharmacology |
5 |
|
propylene glycols - therapeutic use |
5 |
|
protein-serine-threonine kinases - physiology |
5 |
|
protein-tyrosine kinases - physiology |
5 |
|
proteins - genetics |
5 |
|
proteins - metabolism |
5 |
|
proto-oncogene proteins - physiology |
5 |
|
proto-oncogene proteins c-akt |
5 |
|
raf kinases - metabolism |
5 |
|
raffinose - chemistry |
5 |
|
receptors, endothelin - genetics |
5 |
|
receptors, estrogen - analysis |
5 |
|
receptors, progesterone - analysis |
5 |
|
reconstructive surgical procedures - methods |
5 |
|
reference values |
5 |
|
referral and consultation |
5 |
|
regorafenib |
5 |
|
regulatory t cells |
5 |
|
remnant |
5 |
|
reperfusion injury - drug therapy |
5 |
|
reperfusion injury - metabolism - physiopathology |
5 |
|
right lobe graft |
5 |
|
risk assessment |
5 |
|
rna, messenger - analysis |
5 |
|
rna, messenger - blood |
5 |
|
rupture - etiology - mortality - pathology |
5 |
|
sarcoma - diagnosis - etiology - genetics - surgery |
5 |
|
segmentectomy |
5 |
|
serum albumin - analysis |
5 |
|
signal transduction |
5 |
|
signal transduction - drug effects - physiology |
5 |
|
single-blind method |
5 |
|
sirolimus - administration and dosage |
5 |
|
smad inhibitor |
5 |
|
smad2/3/smad4 |
5 |
|
small-for-size graft |
5 |
|
somatostatin - therapeutic use |
5 |
|
sorafenib resistance |
5 |
|
sphingosine - analogs & derivatives |
5 |
|
statistics, nonparametric |
5 |
|
stem cell |
5 |
|
steroids - therapeutic use |
5 |
|
sterol regulatory element binding protein 1 |
5 |
|
stress, mechanical |
5 |
|
survival rate - trends |
5 |
|
t cell exhaustion |
5 |
|
tace |
5 |
|
tamoxifen - therapeutic use |
5 |
|
tissue and organ harvesting - methods |
5 |
|
tissue donors - supply & distribution |
5 |
|
toce |
5 |
|
tomography, x-ray computed |
5 |
|
transcription factors - physiology |
5 |
|
transferrin - analysis |
5 |
|
transplantation, homologous - adverse effects |
5 |
|
ttr gene |
5 |
|
tuberculosis - diagnosis - drug therapy - transmission |
5 |
|
tumor-initiating cell |
5 |
|
up-regulation |
5 |
|
up-regulation - physiology |
5 |
|
upr pathway |
5 |
|
vascular endothelial growth factor a |
5 |
|
vascular endothelial growth factors |
5 |
|
vasoconstriction - physiology |
5 |
|
" surrogate" end point |
4 |
|
78-kda glucose-regulated protein |
4 |
|
abo blood-group system - immunology |
4 |
|
active immunization |
4 |
|
acute rejection |
4 |
|
adenine - analogs and derivatives - therapeutic use |
4 |
|
adenosine |
4 |
|
afp |
4 |
|
allopurinol |
4 |
|
alpha-fetoproteins - analysis |
4 |
|
anastomosis, surgical - adverse effects |
4 |
|
antibody against hepatitis b surface antigen |
4 |
|
antibody formation |
4 |
|
antibody-mediated rejection |
4 |
|
apoa-1 |
4 |
|
associating liver partition and portal vein ligation for staged hepatectomy |
4 |
|
biliary tract neoplasms - complications - mortality |
4 |
|
bilirubin level |
4 |
|
biomaterial |
4 |
|
biomedical research |
4 |
|
blood group incompatibility - immunology |
4 |
|
blood loss, surgical - statistics & numerical data |
4 |
|
blood vessel prosthesis implantation |
4 |
|
bone marrow cells - pathology |
4 |
|
bregs |
4 |
|
carcinoma, hepatocellular - complications - mortality - surgery |
4 |
|
carcinoma, hepatocellular - diagnosis - etiology - surgery |
4 |
|
carcinoma, hepatocellular - diagnosis - surgery |
4 |
|
carcinoma, hepatocellular - epidemiology - etiology - pathology |
4 |
|
carcinoma, hepatocellular - mortality |
4 |
|
carcinoma, hepatocellular - mortality - therapy |
4 |
|
carcinoma, hepatocellular - pathology - surgery - virology |
4 |
|
carcinoma, hepatocellular - therapy |
4 |
|
caspase |
4 |
|
caspase 3 |
4 |
|
cell cycle checkpoint |
4 |
|
chemoembolization |
4 |
|
chemoembolization, therapeutic |
4 |
|
chemotherapy |
4 |
|
china |
4 |
|
cholangiocarcinoma - pathology - surgery |
4 |
|
cholangiopancreatography, endoscopic retrograde - methods - mortality |
4 |
|
cholangitis - etiology - surgery |
4 |
|
cholangitis - mortality - therapy |
4 |
|
choledochostomy |
4 |
|
cholestasis - etiology - surgery |
4 |
|
cholestasis - mortality - surgery - therapy |
4 |
|
cholestasis - surgery |
4 |
|
cholesterol |
4 |
|
chromosomes, human, y |
4 |
|
clinical outcomes |
4 |
|
combined hcc-cc |
4 |
|
complement component |
4 |
|
complex liver surgery |
4 |
|
contraceptives, oral - administration & dosage |
4 |
|
cytokine receptor gp130 - metabolism |
4 |
|
cytotoxicity |
4 |
|
diagnosis prediction |
4 |
|
discriminant analysis |
4 |
|
dna, viral - analysis |
4 |
|
drainage |
4 |
|
drug reaction |
4 |
|
drug-induced liver injury - etiology - metabolism - pathology - surgery |
4 |
|
dual graft |
4 |
|
dyslipidemia |
4 |
|
early-phase |
4 |
|
embryonic liver |
4 |
|
emergency laparoscopic cholecystectomy |
4 |
|
end stage liver disease - surgery - virology |
4 |
|
ercp |
4 |
|
family practice - trends |
4 |
|
fasting glucose |
4 |
|
fatal outcome |
4 |
|
fatty change |
4 |
|
fatty liver - pathology - radiography |
4 |
|
female patient |
4 |
|
fibrosis progression |
4 |
|
fish |
4 |
|
fluorescent antibody technique |
4 |
|
forecasting |
4 |
|
gallbladder |
4 |
|
gender |
4 |
|
glutathione |
4 |
|
gore-tex graft |
4 |
|
graft occlusion, vascular - diagnosis - etiology - physiopathology - surgery |
4 |
|
graft survival - drug effects - physiology |
4 |
|
graft survival - immunology |
4 |
|
graft vs host disease - diagnosis - etiology - pathology |
4 |
|
grafts |
4 |
|
granulin-epithelin precursor |
4 |
|
hbv |
4 |
|
hcc invasiveness |
4 |
|
hcc recurrence |
4 |
|
hemoglobin-based oxygen carrier |
4 |
|
hemostasis, surgical |
4 |
|
hepatectom |
4 |
|
hepatectomy - adverse effects - contraindications - methods - mortality |
4 |
|
hepatectomy - adverse effects - methods |
4 |
|
hepatectomy - adverse effects - methods - mortality |
4 |
|
hepatectomy - adverse effects - mortality - standards |
4 |
|
hepatectomy - statistics and numerical data |
4 |
|
hepatic bipotent cells |
4 |
|
hepatic ischemia reperfusion |
4 |
|
hepatic veins - physiopathology |
4 |
|
hepatic veins - physiopathology - radiography - surgery |
4 |
|
hepatitis |
4 |
|
hepatitis b - complications - pathology - surgery |
4 |
|
hepatitis b - prevention & control - surgery - therapy |
4 |
|
hepatitis b antibodies - analysis |
4 |
|
hepatitis b e antigens - analysis |
4 |
|
hepatitis b immune globulin |
4 |
|
hepatitis b vaccines - therapeutic use |
4 |
|
hepatitis b virus - genetics - immunology |
4 |
|
hepatitis b, chronic - drug therapy - pathology - virology |
4 |
|
hepatitis b, chronic - etiology - immunology - prevention & control |
4 |
|
hepatitis, chronic - complications - surgery |
4 |
|
hepatocytes - metabolism - pathology - transplantation |
4 |
|
hepatopancreaticobiliary surgery |
4 |
|
hernia - etiology |
4 |
|
high intensity focused ultrasound |
4 |
|
hilar cholangiocarcinoma |
4 |
|
histocompatibility testing |
4 |
|
histology |
4 |
|
hla |
4 |
|
hla antigens - analysis |
4 |
|
hsp70 heat-shock proteins - genetics - metabolism |
4 |
|
hydroge |
4 |
|
icg fluorescence |
4 |
|
imaging |
4 |
|
immunity |
4 |
|
immunization |
4 |
|
indocyanine green |
4 |
|
indocyanine green - diagnostic use |
4 |
|
inflammasome |
4 |
|
inflammatory responses |
4 |
|
inoperable |
4 |
|
insulin - pharmacology |
4 |
|
interferon-gamma |
4 |
|
interleukin-6 - genetics - metabolism |
4 |
|
internal hernia |
4 |
|
interventional radiology |
4 |
|
intestinal diseases - etiology - surgery |
4 |
|
intestinal obstruction |
4 |
|
intestinal obstruction - etiology - surgery |
4 |
|
intravital imaging |
4 |
|
ionizing radiation |
4 |
|
ischemic injury |
4 |
|
kupffer cells - cytology |
4 |
|
laparoscopic ultrasonography |
4 |
|
laparoscopy - statistics and numerical data |
4 |
|
left lobe graft |
4 |
|
lipid metabolism |
4 |
|
lipoprotein |
4 |
|
live donor |
4 |
|
liver - drug effects - pathology |
4 |
|
liver - metabolism - pathology |
4 |
|
liver - pathology - radiography - surgery |
4 |
|
liver circulation |
4 |
|
liver circulation - drug effects |
4 |
|
liver cirrhosis - complications - surgery |
4 |
|
liver cirrhosis - diagnosis - surgery |
4 |
|
liver cirrhosis - epidemiology - etiology - pathology |
4 |
|
liver complications |
4 |
|
liver graft |
4 |
|
liver neoplasms - complications - mortality - surgery |
4 |
|
liver neoplasms - diagnosis - etiology - surgery |
4 |
|
liver neoplasms - diagnosis - surgery |
4 |
|
liver neoplasms - epidemiology - etiology - pathology |
4 |
|
liver neoplasms - metabolism - pathology - surgery |
4 |
|
liver neoplasms - mortality |
4 |
|
liver neoplasms - mortality - therapy |
4 |
|
liver neoplasms - pathology - surgery - virology |
4 |
|
liver neoplasms - surgery - therapy |
4 |
|
liver regeneration |
4 |
|
liver steatosis |
4 |
|
liver transplantation - immunology - methods |
4 |
|
liver tumor |
4 |
|
living donor transplantation |
4 |
|
living donors - psychology - supply and distribution |
4 |
|
lliver neoplasms |
4 |
|
lymphocytes - pathology |
4 |
|
macrophage activation |
4 |
|
macrophages - cytology |
4 |
|
mass spectrometry |
4 |
|
mdsc |
4 |
|
member d |
4 |
|
mhc class i chain-related molecule a |
4 |
|
mir-1246 |
4 |
|
mixed tumor, malignant - pathology - surgery |
4 |
|
modified hai score |
4 |
|
natural-killer group 2 |
4 |
|
nf-κb |
4 |
|
notch signaling |
4 |
|
occult hbv co-infection |
4 |
|
oncology |
4 |
|
open conversion |
4 |
|
open liver resection |
4 |
|
organ preservation - methods |
4 |
|
organ preservation solutions |
4 |
|
pancreatic neoplasms - complications |
4 |
|
parenteral nutrition |
4 |
|
pattern |
4 |
|
pediatric |
4 |
|
perforin |
4 |
|
phlebography - methods |
4 |
|
phosphonic acids - therapeutic use |
4 |
|
pi3-kinase/akt |
4 |
|
pneumocystis jirovecii |
4 |
|
pneumocystis pneumonia |
4 |
|
post-liver transplant |
4 |
|
postoperative complications - epidemiology - mortality |
4 |
|
postoperative cytokines |
4 |
|
preoperative biliary drainage |
4 |
|
preventive medicine - methods |
4 |
|
primary biliary cirrhosis |
4 |
|
pringle manoeuvre |
4 |
|
protein interaction |
4 |
|
radiofrequency |
4 |
|
radiosurgery |
4 |
|
raffinose |
4 |
|
recurrence - prevention & control |
4 |
|
recurrent chronic hepatitis c virus |
4 |
|
relapsed infection due to hbv |
4 |
|
reperfusion injury - physiopathology |
4 |
|
resectability |
4 |
|
response marker |
4 |
|
retreatment |
4 |
|
review |
4 |
|
right lobe |
4 |
|
ruptured hepatocellular carcinoma |
4 |
|
safety |
4 |
|
sepsis |
4 |
|
severe fibrosis |
4 |
|
single institution |
4 |
|
skin - pathology |
4 |
|
small for size liver graft |
4 |
|
small-for size graft |
4 |
|
small-for-size fatty graft injury |
4 |
|
split graft |
4 |
|
steatotic donor |
4 |
|
steatotic liver graft |
4 |
|
stress |
4 |
|
surgical procedures, operative |
4 |
|
survivor |
4 |
|
tacrolimus |
4 |
|
technique |
4 |
|
therapeutic potential |
4 |
|
therapeutic target |
4 |
|
thermal ablation |
4 |
|
tissue and organ harvesting - adverse effects - methods |
4 |
|
tissue and organ harvesting - adverse effects - mortality - standards |
4 |
|
transmembrane protein 47 |
4 |
|
transplant outcomes |
4 |
|
transplant research |
4 |
|
transplantation chimera |
4 |
|
transplants |
4 |
|
triglyceride |
4 |
|
tumor necrosis factor-alpha - genetics - metabolism |
4 |
|
tumor-suppressive protein |
4 |
|
tumour recurrence |
4 |
|
ultrastructure |
4 |
|
urology and nephrology |
4 |
|
vascular reconstruction |
4 |
|
vascular resection |
4 |
|
vein graft |
4 |
|
vena cava, inferior - surgery |
4 |
|
y chromosome - genetics |
4 |
|
adenosine - pharmacology |
3 |
|
adoptive immunity transfer |
3 |
|
alemtuzumab |
3 |
|
alternative splicing events |
3 |
|
aminopyrine - diagnostic use |
3 |
|
aminopyrine breath test |
3 |
|
amyloidosis |
3 |
|
antineoplastic agents - therapeutic use |
3 |
|
bacterial infections |
3 |
|
belatacept |
3 |
|
bias (epidemiology) |
3 |
|
bile |
3 |
|
bile ducts - metabolism - surgery |
3 |
|
bile ducts - pathology - surgery |
3 |
|
bile ducts, intrahepatic |
3 |
|
bile ducts, intrahepatic - pathology |
3 |
|
bile ducts, intrahepatic - surgery |
3 |
|
biliary tract - abnormalities - radiography |
3 |
|
biliary tract diseases |
3 |
|
biliary tract diseases - etiology |
3 |
|
biliary tract diseases - etiology - therapy |
3 |
|
biliary tract neoplasms - therapy |
3 |
|
biliary tract surgical procedures - adverse effects |
3 |
|
bleeding |
3 |
|
blood glucose - analysis |
3 |
|
blood loss, surgical - physiopathology |
3 |
|
blood transfusion, autologous |
3 |
|
body surface area |
3 |
|
breath tests |
3 |
|
calcineurin inhibitor |
3 |
|
calcium - diagnostic use |
3 |
|
cancer hallmarks |
3 |
|
carcinoma, hepatocellular - drug therapy - genetics - mortality |
3 |
|
carcinoma, hepatocellular - drug therapy - pathology - surgery |
3 |
|
carcinoma, hepatocellular - pathology - surgery - ultrasonography |
3 |
|
catheterization, central venous |
3 |
|
cell delivery |
3 |
|
central bisectionectomy |
3 |
|
chemotherapy, adjuvant |
3 |
|
chilaiditi's sign |
3 |
|
cholangiography |
3 |
|
cholangiopancreatography, endoscopic retrograde |
3 |
|
cholangitis |
3 |
|
cholangitis-therapy |
3 |
|
cholecystectomy, laparoscopic - adverse effects |
3 |
|
cholecystitis - surgery - ultrasonography |
3 |
|
cholelithiasis - diagnosis - therapy |
3 |
|
cholelithiasis - surgery - therapy |
3 |
|
cholestasis - epidemiology - metabolism - surgery |
3 |
|
cholestasis - physiopathology - surgery |
3 |
|
cisplatin - administration & dosage |
3 |
|
cisplatin resistance |
3 |
|
clinical trials as topic |
3 |
|
colon - radiography |
3 |
|
combined |
3 |
|
constriction, pathologic |
3 |
|
corticosteroid |
3 |
|
cost-benefit analysis |
3 |
|
cyclosporine |
3 |
|
deceased-donor |
3 |
|
dendritic cells - pathology |
3 |
|
diagnosis, differential |
3 |
|
diaphragm - radiography |
3 |
|
distal pancreatectomy |
3 |
|
double-blind method |
3 |
|
drainage-methods |
3 |
|
embolization, therapeutic |
3 |
|
embolization, therapeutic - methods |
3 |
|
endoscopy,-gastrointestinal |
3 |
|
enucleation |
3 |
|
epcs |
3 |
|
epidemiologic factors |
3 |
|
erectile dysfunction |
3 |
|
estimated standard liver weight |
3 |
|
everolimus |
3 |
|
fibrosis |
3 |
|
flexible endoscopy |
3 |
|
flowmetry |
3 |
|
follicular dendritic cell |
3 |
|
fulminant hepatic failure |
3 |
|
gallstones-surgery |
3 |
|
glucose - pharmacology |
3 |
|
graft shortage |
3 |
|
hbv vaccination |
3 |
|
hcv |
3 |
|
heart |
3 |
|
hepatic |
3 |
|
hepatic duct, common - pathology |
3 |
|
hepatic duct, common - surgery |
3 |
|
hepatic i/r injury |
3 |
|
hepatic ischemia/reperfusion |
3 |
|
hepatic veins |
3 |
|
hepatic veins - transplantation |
3 |
|
hepatitis, chronic - pathology - surgery |
3 |
|
hepatobiliary |
3 |
|
hepatocellular cancer |
3 |
|
hepatolithiasis |
3 |
|
hormones - administration & dosage |
3 |
|
hyperalimentation |
3 |
|
hypogonadism |
3 |
|
icg |
3 |
|
immunoglobulin |
3 |
|
immunology |
3 |
|
in vivo applications |
3 |
|
indocyanine green retention |
3 |
|
inferior vena cava |
3 |
|
inflammatory pseudotumour |
3 |
|
inflow control |
3 |
|
insulin - blood |
3 |
|
insulinoma - diagnosis - surgery |
3 |
|
intensity |
3 |
|
intensive care |
3 |
|
interferon-alpha - therapeutic use |
3 |
|
interventional endoscopy |
3 |
|
intestinal perforation - radiography |
3 |
|
intraoperative complications - etiology |
3 |
|
intraoperative complications - etiology - prevention & control |
3 |
|
ip10 |
3 |
|
jejunostomy - methods |
3 |
|
laparoscopic surgery |
3 |
|
laparotomy |
3 |
|
leiomyosarcoma |
3 |
|
linear models |
3 |
|
liver - blood supply |
3 |
|
liver - blood supply - surgery |
3 |
|
liver - surgery |
3 |
|
liver cirrhosis - pathology - surgery |
3 |
|
liver failure - etiology |
3 |
|
liver failure - radiography |
3 |
|
liver failure - surgery - therapy |
3 |
|
liver neoplasm |
3 |
|
liver neoplasms |
3 |
|
liver neoplasms - drug therapy - genetics - mortality |
3 |
|
liver neoplasms - drug therapy - pathology - surgery |
3 |
|
liver neoplasms - pathology - radiography - surgery |
3 |
|
liver neoplasms - pathology - surgery - ultrasonography |
3 |
|
liver regeneration - physiology |
3 |
|
liver transplantation - contraindications - methods |
3 |
|
liver transplantation - immunology - methods - mortality |
3 |
|
liver transplantation - methods - psychology |
3 |
|
liver transplantation using steatotic graft |
3 |
|
living donation |
3 |
|
living donors - psychology |
3 |
|
living-related liver donors |
3 |
|
lymphoma, follicular - pathology - radiography - surgery |
3 |
|
macrophage activation - immunology |
3 |
|
macrophages - immunology |
3 |
|
magnet‐driven |
3 |
|
metabolism and immune cells |
3 |
|
microrobots |
3 |
|
microvascular surgery |
3 |
|
mtor inhibitor |
3 |
|
multiple endocrine neoplasia type 1 - surgery |
3 |
|
mycophenolate |
3 |
|
non-colorectal liver metastasis |
3 |
|
nutritional support |
3 |
|
obstructive jaundice |
3 |
|
organ donation |
3 |
|
organ preservation solutions - pharmacology |
3 |
|
pancreatic insulinoma |
3 |
|
pancreatic neoplasms - diagnosis - surgery |
3 |
|
pancreatic pseudocyst - diagnosis |
3 |
|
pancreatitis - blood - etiology - prevention & control |
3 |
|
pancreatitis - blood - mortality |
3 |
|
pancreatitis-surgery |
3 |
|
photoacoustic imaging |
3 |
|
platelet apheresis |
3 |
|
portal inflow |
3 |
|
portal vein thrombosis |
3 |
|
portoenterostomy |
3 |
|
postoperative complications - epidemiology - prevention & control |
3 |
|
postoperative complications - etiology - therapy |
3 |
|
postoperative complications - radiography - therapy |
3 |
|
potassium chloride - pharmacology |
3 |
|
pregnancy |
3 |
|
quality of life |
3 |
|
questionnaires |
3 |
|
raffinose - pharmacology |
3 |
|
rapamycin |
3 |
|
regional blood flow/physiology |
3 |
|
regression analysis |
3 |
|
renal veins - surgery - ultrasonography |
3 |
|
resection margin |
3 |
|
right liver |
3 |
|
saphenous vein - surgery |
3 |
|
sequential |
3 |
|
sex factors |
3 |
|
sexual dysfunction |
3 |
|
simplifying |
3 |
|
sirolimus |
3 |
|
soft tissue sarcoma |
3 |
|
somatostatin - administration & dosage |
3 |
|
sotrastaurin |
3 |
|
sphincterotomy, endoscopic - adverse effects - mortality - statistics & numerical data |
3 |
|
sphincterotomy,-endoscopic-adverse-effects |
3 |
|
sphincterotomy,-endoscopic-mortality |
3 |
|
splanchnic circulation - physiology |
3 |
|
splenic artery |
3 |
|
splenic vein - surgery - ultrasonography |
3 |
|
spouses |
3 |
|
subclavian vein - surgery |
3 |
|
subphrenic abscess - radiography |
3 |
|
surgical approaches |
3 |
|
surgical procedures, elective |
3 |
|
t lymphocyte function |
3 |
|
tenofovir |
3 |
|
thrombocytosis |
3 |
|
tissue and organ harvesting |
3 |
|
tissue and organ procurement - methods |
3 |
|
tissue and organ procurement - statistics and numerical data |
3 |
|
tissue donors - supply and distributionhttp://hub.hku.hk/tools/edit-item |
3 |
|
tofacitinib |
3 |
|
transplantation, liver |
3 |
|
transplants - standards |
3 |
|
treg |
3 |
|
tregs |
3 |
|
tumor metastasis |
3 |
|
ultrasonography, interventional |
3 |
|
urea - blood |
3 |
|
vascular endothelial growth factor a - biosynthesis - immunology |
3 |
|
vascular endothelial growth factor receptor-2 - biosynthesis - immunology |
3 |
|
vena caval tumor |
3 |
|
venoplasty |
3 |
|
viral infections |
3 |
|
voclosporin |
3 |
|
yq23 |
3 |
|
abo blood-group system - adverse effects |
2 |
|
adenocarcinoma - secondary - surgery |
2 |
|
advanced hepatocellular carcinoma |
2 |
|
alkaline phosphatase - blood |
2 |
|
anastomosis, roux-en-y - standards |
2 |
|
anemia, hemolytic - etiology |
2 |
|
asian continental ancestry group |
2 |
|
bile duct |
2 |
|
bile duct neoplasms - radiography - surgery |
2 |
|
bile duct stricture |
2 |
|
bile ducts -- surgery. |
2 |
|
biliary complication |
2 |
|
biliary tract surgical procedures - standards |
2 |
|
blood banks |
2 |
|
blood grouping and crossmatching |
2 |
|
bloodless liver resection |
2 |
|
carcinoma, hepatocellular - blood |
2 |
|
carcinoma, hepatocellular - drug therapy - metabolism - pathology |
2 |
|
carcinoma, squamous cell - secondary - surgery |
2 |
|
cardia |
2 |
|
chimerism |
2 |
|
cholangiopancreatography, endoscopic retrograde - adverse effects - mortality |
2 |
|
choledocholithiasis |
2 |
|
covalently closed circular dna |
2 |
|
de-novo hepatitis b virus infection |
2 |
|
dna |
2 |
|
drain |
2 |
|
end-stage liver diseases |
2 |
|
endoscopic retrograde cholangiopancreatography |
2 |
|
endoscopy |
2 |
|
epoprostenol - administration & dosage |
2 |
|
erythrocytes - immunology |
2 |
|
esophageal neoplasms - surgery |
2 |
|
estimated standard liver volume |
2 |
|
expanded criteria |
2 |
|
exploration |
2 |
|
extended right lobe graft |
2 |
|
gallstones - radiography - therapy |
2 |
|
gamma-glutamyltransferase - blood |
2 |
|
graft rejection - immunology |
2 |
|
graft vs host disease - etiology |
2 |
|
hematopoietic stem cells - immunology |
2 |
|
heparanase |
2 |
|
hepatic duct, common - radiography - surgery |
2 |
|
hepatic injury |
2 |
|
hepatic venous outflow obstruction |
2 |
|
hepatitis b - surgery - therapy |
2 |
|
hepatitis b core antigen |
2 |
|
hepatitis b surface antigen |
2 |
|
hepatitis c virus |
2 |
|
hepatocellular cacinoma |
2 |
|
hepatocellular carcinoma metastasis |
2 |
|
hernia |
2 |
|
hilar plate |
2 |
|
history, 20th century |
2 |
|
inguinal |
2 |
|
insulinoma |
2 |
|
international cooperation |
2 |
|
isoantibodies - blood |
2 |
|
klatskin's tumor - radiography - surgery |
2 |
|
laparoscopic |
2 |
|
laparoscopic exploration of common bile duct |
2 |
|
laparotomy - adverse effects |
2 |
|
lithotripsy - methods |
2 |
|
liver - transplantation - china - hong kong. |
2 |
|
liver - transplantation. |
2 |
|
liver -- surgery. |
2 |
|
liver / transplantation |
2 |
|
liver metastases |
2 |
|
liver neoplasms - drug therapy - metabolism - pathology |
2 |
|
liver neoplasms - secondary |
2 |
|
liver transection |
2 |
|
liver transplantation - ethnology - immunology |
2 |
|
liver transplantation - history - methods |
2 |
|
liver transplantation - history - methods - trends |
2 |
|
liver tumour |
2 |
|
living donors - history |
2 |
|
localization |
2 |
|
loco-regional therapy |
2 |
|
lung neoplasms - drug therapy - metabolism - secondary |
2 |
|
matrix metallopeptidase |
2 |
|
mif |
2 |
|
mrecist |
2 |
|
neuroendocrine tumor |
2 |
|
oesophagus |
2 |
|
organ donors |
2 |
|
pancreatitis |
2 |
|
percutaneous transhepatic biliary drainage |
2 |
|
peritoneal neoplasms - secondary |
2 |
|
plasmapheresis |
2 |
|
postoperative complications - etiology - mortality - surgery |
2 |
|
ppar gamma - agonists - metabolism |
2 |
|
pparg |
2 |
|
pregnancy complications - surgery |
2 |
|
prophylactic therapy |
2 |
|
purpura, thrombotic thrombocytopenic - blood - chemically induced |
2 |
|
resection strategy |
2 |
|
right lobe living donor liver transplantation |
2 |
|
salvage therapy |
2 |
|
seroepidemiologic studies |
2 |
|
seroma |
2 |
|
small for size syndrome |
2 |
|
split liver transplantation |
2 |
|
stents - adverse effects |
2 |
|
stomach neoplasms - surgery |
2 |
|
surgical resection |
2 |
|
syndrome |
2 |
|
tacrolimus - administration & dosage - adverse effects |
2 |
|
thiazolidinediones - pharmacology |
2 |
|
thrombocytopenia - etiology |
2 |
|
tissue inhibitors of metalloproteinase |
2 |
|
treatment |
2 |
|
trisectionectomy |
2 |
|
ttp |
2 |
|
ultrasonography |
2 |
|
abo blood-group system |
1 |
|
alpha-fetoproteins - metabolism |
1 |
|
antibody formation - immunology |
1 |
|
arteriovenous malformations - diagnosis - radiography - surgery |
1 |
|
blood group incompatibility |
1 |
|
calcineurin - antagonists and inhibitors |
1 |
|
carcinoma, hepatocellular - blood - surgery |
1 |
|
causes |
1 |
|
cholecystectomy, laparoscopic |
1 |
|
cholelithiasis - surgery |
1 |
|
clinical manifestations |
1 |
|
covid-19 |
1 |
|
data collection |
1 |
|
diagnostic errors |
1 |
|
emergency surgery |
1 |
|
far east |
1 |
|
fatty liver - diagnosis |
1 |
|
filtration efficiency |
1 |
|
global |
1 |
|
graft rejection - blood |
1 |
|
graft rejection - epidemiology |
1 |
|
graft rejection - prevention and control |
1 |
|
health surveys |
1 |
|
hepatectomy - mortality |
1 |
|
hepatic artery |
1 |
|
hepatitis - diagnosis |
1 |
|
hepatitis b - complications - immunology |
1 |
|
hepatitis b - diagnosis - immunology - mortality |
1 |
|
hepatitis b - immunology |
1 |
|
hepatitis b vaccines - immunology |
1 |
|
home-made masks |
1 |
|
immunity, cellular - immunology |
1 |
|
liver - cancer - treatment. |
1 |
|
liver cirrhosis - etiology - surgery |
1 |
|
liver failure, acute - therapy |
1 |
|
liver transplantation - adverse effects - immunology - mortality |
1 |
|
liver transplantation - immunology - mortality |
1 |
|
liver transplantation - trends |
1 |
|
living donors - statistics & numerical data |
1 |
|
living donors - statistics and numerical data |
1 |
|
maintenance therapy |
1 |
|
models of care |
1 |
|
nano-aerosols |
1 |
|
nephrotoxicity |
1 |
|
non-operative treatment |
1 |
|
organ shortage |
1 |
|
osmolar concentration |
1 |
|
package charge (住院打包收費) |
1 |
|
pancreatitis - diagnosis - etiology |
1 |
|
pandemic |
1 |
|
patient satisfaction (患者滿意度) |
1 |
|
postoperative complications - immunology - virology |
1 |
|
rectal cancer |
1 |
|
reoperation - statistics & numerical data |
1 |
|
research design |
1 |
|
risk |
1 |
|
sarcoma - diagnosis - pathology |
1 |
|
sars-cov-2 |
1 |
|
soft tissue neoplasms - diagnosis - pathology |
1 |
|
splenic artery - surgery |
1 |
|
surgical disease (手術病例) |
1 |
|
thigh - blood supply |
1 |
|
thrombosis - etiology |
1 |
|
tissue and organ procurement |
1 |
|
transanal endoscopic operation |
1 |
|
transanal total mesorectal excision |
1 |
|
treatment failure |
1 |
